8 assets in Carcinoma Of Urethra

Therapeutic assets addressing Carcinoma Of Urethra, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Carcinoma Of Urethra	University of Southern California	P3	BB (70)
Bortezomib Carcinoma Of Urethra	M.D. Anderson Cancer Center	P2	B (62)
Cabozantinib Carcinoma Of Urethra	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Carcinoma Of Urethra	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Carcinoma Of Urethra	M.D. Anderson Cancer Center	P2	CCC (53)
Tocilizumab Carcinoma Of Urethra	M.D. Anderson Cancer Center	P2	CCC (53)
64cu-grip b Carcinoma Of Urethra	Rahul Aggarwal	P1/2	CCC (48)